Tag: GW Pharmaceuticals

Avatar photoDebra BorchardtFebruary 16, 2021
GWPH.png
Business

GW Pharmaceuticals Beats Estimates For Revenues

5min00
GW Pharmaceuticals plc (Nasdaq: GWPH) announced that the total revenue for the fourth quarter ending December 31, 2020, was $148.2 million versus $109.1 million for the quarter ended December 31, 2019. This beat the analyst estimates according to Yahoo Finance by $3.66 million. The net loss for the quarter ended December 31, 2020, was $29.1 […]
CONTINUE READING
Avatar photoStaffFebruary 4, 2021
stockmarket.jpg
Business

GW Pharmaceuticals Stock Pops On Acquisition

9min00
Editors Note: This story is reprinted with permission from Streetwise Reports. Biopharmaceutical firm GW Pharmaceuticals Plc (GWPH:NASDAQ), which utilizes its proprietary cannabinoid product platform to develop and commercialize new medicines across a broad range of disease areas, and global biopharmaceutical company Jazz Pharmaceuticals Plc (JAZZ:NASDAQ), announced that the companies have entered into a definitive agreement for Jazz Pharmaceuticals to […]
CONTINUE READING
Avatar photoDebra BorchardtFebruary 3, 2021
shutterstock_256424509-1280x853.jpg
Business

Jazz Pharmaceuticals Is Buying GW Pharmaceuticals in $7.2 Billion Deal

5min00
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is buying GW Pharmaceuticals plc (Nasdaq: GWPH) in a deal valued at $7.2 billion or $6.7 billion net of GW cash. Jazz will acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares. The transaction, which has been unanimously approved by the Boards of Directors of […]
CONTINUE READING
Avatar photoDebra BorchardtJanuary 11, 2021
epidiolex-medical-marijuana-1280x800-1280x800.jpg
Business

GW Pharmaceuticals Says Epidiolex Sales Continued To Increase In Fourth Quarter

5min00
Ahead of the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, GW Pharmaceuticals plc (Nasdaq: GWPH)released preliminary, unaudited net product sales for the fourth quarter and full-year 2020 and key priorities for 2021. GW Pharma said it expects total net product sales to be approximately $148 million for the fourth quarter and approximately $526 million […]
CONTINUE READING
Avatar photoStaffJuly 1, 2020
money2.jpg
Business

The Richest Cannabis Businesses in 2020

8min00
Editors Note: This is a guest post. More and more countries decide to legalize cannabis and give entrepreneurs a chance to make money and keep the economy.  In 2019, the marihuana stocks were supposed to prove their worth on Wall Street by generating steady profits. However, things didn’t go according to the plan. Many investors […]
CONTINUE READING
Avatar photoDebra BorchardtJune 30, 2020
Sativex.jpg
Business

Move Over Epidiolex, Sativex Wants The Spotlight

5min00
GW Pharmaceuticals plc (NASDAQ:GWPH) has pushed the legalization of cannabis ahead with its work on the drug Epidiolex. Now the company is making its plans for its other cannabis drug Sativex known and it’s impressive and hopeful. The company is announcing its plans for its pipeline product nabiximols to the U.S. market. This strategy includes […]
CONTINUE READING

Older Posts

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis

READ MORE
Recent Tweets
Company